专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070104685A1 Synthetic gene encoding human carcinoembryonic antigen and uses thereof 审中-公开
标题翻译：编码人癌胚抗原的合成基因及其用途
公开(公告)号：US20070104685A1
公开(公告)日：2007-05-10
申请号：US10555744
申请日：2004-05-03
申请人： Nicola La Monica , Armin Lahm , Carmela Mennuni , Rocco Savino
发明人： Nicola La Monica , Armin Lahm , Carmela Mennuni , Rocco Savino
IPC分类号： A61K48/00 , C12Q1/68 , C07H21/04 , C12P21/06 , C12N15/861 , C07K14/82
CPC分类号： C07K14/4748 , A61K39/00 , A61K2039/53 , C07K14/70503 , C12N2799/022
摘要： Synthetic polynucleotides encoding human carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being codon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying codon-optimed human CEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
摘要翻译：提供了编码人癌胚抗原（CEA）的合成多核苷酸，所述合成多核苷酸被密码子优化用于在人细胞环境中表达。编码CEA的基因通常与人类癌的发展有关。本发明提供了引发或增强由CEA肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常CEA表达与癌症或其发展相关。本发明具体提供携带密码子优化的人CEA的腺病毒载体和质粒构建体，并公开了它们在预防和治疗癌症的疫苗和药物组合物中的用途。

2. 发明申请

US20080090778A1 Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof 有权
标题翻译：端粒酶逆转录酶融合蛋白，编码它的核苷酸及其用途
公开(公告)号：US20080090778A1
公开(公告)日：2008-04-17
申请号：US11974067
申请日：2007-10-11
申请人： Elisa Scarselli , Carmela Mennuni , Nicola La Monica , Gennaro Ciliberto
发明人： Elisa Scarselli , Carmela Mennuni , Nicola La Monica , Gennaro Ciliberto
IPC分类号： A61K31/70 , C07H21/04 , C07K16/00 , C12N15/00 , C12N5/00
CPC分类号： C07K14/245 , C07K2319/00 , C07K2319/036 , C12N9/1241 , C12Y207/07049
摘要： Polynucleotides encoding telomerase reverse transcriptase (TERT) fusion proteins are provided, the TERT fusion proteins comprising a TERT protein, or functional variant thereof, fused to a substantial portion of the B subunit of heat labile enterotoxin (LTB). TERT variants useful in TERT-LTB fusion proteins of the invention comprise mutations that function to eliminate telomerase catalytic activity. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type TERT. TERT expression is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the TERT tumor-associated antigen, wherein aberrant TERT expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding TERT fusion proteins and TERT variants and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
摘要翻译：提供了编码端粒酶逆转录酶（TERT）融合蛋白的多核苷酸，包含与热不稳定肠毒素（LTB）的B亚基的大部分融合的TERT蛋白或其功能变体的TERT融合蛋白。在本发明的TERT-LTB融合蛋白中有用的TERT变体包含用于消除端粒酶催化活性的突变。本发明的多核苷酸可以在哺乳动物中引发免疫应答，在优选的实施方案中，其比由野生型TERT引起的免疫应答更强。 TERT表达通常与人类癌的发展有关。本发明提供了引发或增强对由TERT肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常TERT表达与癌症或其发展相关。本发明具体提供了携带编码TERT融合蛋白和TERT变体的多核苷酸的腺病毒载体和质粒构建体，并公开了它们在预防和治疗癌症的疫苗和药物组合物中的用途。

3. 发明授权

US08017387B2 Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof 有权
标题翻译：端粒酶逆转录酶融合蛋白，编码它的核苷酸及其用途
公开(公告)号：US08017387B2
公开(公告)日：2011-09-13
申请号：US11974067
申请日：2007-10-11
申请人： Elisa Scarselli , Carmela Mennuni , Nicola La Monica , Gennaro Ciliberto
发明人： Elisa Scarselli , Carmela Mennuni , Nicola La Monica , Gennaro Ciliberto
IPC分类号： C12N15/00 , C12N5/10
CPC分类号： C07K14/245 , C07K2319/00 , C07K2319/036 , C12N9/1241 , C12Y207/07049
摘要： Polynucleotides encoding telomerase reverse transcriptase (TERT) fusion proteins are provided, the TERT fusion proteins comprising a TERT protein, or functional variant thereof, fused to a substantial portion of the B subunit of heat labile enterotoxin (LTB). TERT variants useful in TERT-LTB fusion proteins of the invention comprise mutations that function to eliminate telomerase catalytic activity. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type TERT. TERT expression is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the TERT tumor-associated antigen, wherein aberrant TERT expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding TERT fusion proteins and TERT variants and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
摘要翻译：提供了编码端粒酶逆转录酶（TERT）融合蛋白的多核苷酸，包含与热不稳定肠毒素（LTB）的B亚基的大部分融合的TERT蛋白或其功能变体的TERT融合蛋白。在本发明的TERT-LTB融合蛋白中有用的TERT变体包含用于消除端粒酶催化活性的突变。本发明的多核苷酸可以在哺乳动物中引发免疫应答，在优选的实施方案中，其比由野生型TERT引起的免疫应答更强。 TERT表达通常与人类癌的发展有关。本发明提供了引发或增强对由TERT肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常TERT表达与癌症或其发展相关。本发明具体提供了携带编码TERT融合蛋白和TERT变体的多核苷酸的腺病毒载体和质粒构建体，并公开了它们在预防和治疗癌症的疫苗和药物组合物中的用途。

4. 发明申请

US20050004055A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue 审中-公开
标题翻译：增加核酸分子进入宿主组织的电 - 基因转移
公开(公告)号：US20050004055A1
公开(公告)日：2005-01-06
申请号：US10495669
申请日：2002-11-21
申请人： Elena Fattori , Nicola La Monica , Carmela Mennuni
发明人： Elena Fattori , Nicola La Monica , Carmela Mennuni
IPC分类号： C12N15/09 , A61K31/7088 , A61K31/711 , A61K38/47 , A61K45/00 , A61K47/42 , A61M37/00 , A61P43/00 , C12N5/10 , A61K48/00
CPC分类号： A61K31/711 , A61K38/47 , A61K2300/00
摘要： A method of delivering a pharmaceutical agent, such as a nucleic acid molecule, to a vertebrate host is disclosed which comprises combining the synergistic steps of electrical stimulation with administration of a biologically active amount of hyaluronidase. Additionally, formulations which comprise hyaluronidase and a pharmaceutical agent, such as a nucleic acid molecule, are disclosed. The hyaluronidase preparation is preferably administered prior to or simultaneous with the pharmaceutical agent and in conjunction with an applied electrical stimulation, thus affecting increased transfer of the population of a pharmaceutical agent into the target tissue when compared to the affect of electrical stimulation alone. The combination of hyaluronidase administration and electrostimulation results in a substantial increase in the transfer of the pharmaceutical agent, such as a nucleic acid molecule, to the target vertebrate host tissue.
摘要翻译：公开了将药剂如核酸分子递送至脊椎动物宿主的方法，其包括将电刺激的协同步骤与施用生物活性量的透明质酸酶组合。此外，公开了包含透明质酸酶和药剂如核酸分子的制剂。透明质酸酶制剂优选在药物之前或与药剂同时施用，并与所施加的电刺激结合施用，因此与单独的电刺激的影响相比，影响药物剂群进入靶组织的增加的转移。透明质酸酶施用和电刺激的组合导致药剂如核酸分子转移到目标脊椎动物宿主组织的显着增加。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式